Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Jia, Zhanjun ^a   Zhang, Yue ^a   Ding, Guixia ^a   Heiney, Kristina Marie ^b   Huang, Songming ^a   Zhang, Aihua ^a  

^a CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; CYCLOOXYGENASE 2; ISOMERASE; PROSTAGLANDIN E SYNTHASE; PTGES PROTEIN, HUMAN;

DRUG TOXICITY; GENE DISRUPTION; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENAL DIABETES; RENAL PROTECTION; REVIEW; ANIMAL; ENZYMOLOGY; GENETICS; KIDNEY; METABOLISM;

ANIMALS; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY; PROSTAGLANDIN-E SYNTHASES;

EID: 84924071355     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/147894     Document Type: Review

References (93)

1. The global issue of kidney disease The Lancet, vol. 382, no. 9887, p. 101, 2013.
2. T. Z. Ali, I. Khan,W. Simpson et al., "Incidence and outcomes in acute kidney injury: a comprehensive population-based study," Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1292-1298, 2007.
3. N. H. Lameire, A. Bagga, D. Cruz et al., "Acute kidney injury: an increasing global concern," The Lancet, vol. 382, no. 9887, pp. 170-179, 2013.
4. P. Dennen, I. S. Douglas, and R. Anderson, "Acute kidney injury in the intensive care unit: an update and primer for the intensivist," Critical Care Medicine, vol. 38, no. 1, pp. 261-275, 2010.
5. T.-G. Cui, T. Ichikawa, M. Yang, X. Dong, J. Li, and T. Cui, "An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy," Biochemical and Biophysical Research Communications, vol. 390, no. 2, pp. 307-312, 2009.
6. B. Rodr'iguez-Iturbe and G. G. Garc'ia, "The role of tubulointerstitial inflammation in the progression of chronic renal failure," Nephron Clinical Practice, vol. 116, no. 2, pp. c81-c87, 2010.
7. G. Zheng, Y. Wang, D. Mahajan, X. Qin, S. I. Alexander, and D. C. H. Harris, "The role of tubulointerstitial inflammation," Kidney International, vol. 67, no. 94, pp. S96-S100, 2005.
8. G. R. Kinsey, R. Sharma, and M. D. Okusa, "Regulatory T cells in AKI," Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1720-1726, 2013.
9. C.-M. Hao and M.D. Breyer, "Physiologic and pathophysiologic roles of lipidmediators in the kidney," Kidney International, vol. 71, no. 11, pp. 1105-1115, 2007.
10. Z. Jia,N. Wang, T. Aoyagi,H. Wang, H. Liu, and T. Yang, "Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis," Kidney International, vol. 79, no. 1, pp. 77-88, 2011.
11. Z. Jia, H. Wang, and T. Yang, "Microsomal prostaglandin e synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction," Hypertension, vol. 59, no. 1, pp. 122-128, 2012.
12. C.-M. Hao and M. D. Breyer, "Physiological regulation of prostaglandins in the kidney," Annual Review of Physiology, vol. 70, pp. 357-377, 2008.
13. R. Nasrallah, R. Hassouneh, and R. L. Hebert, "Chronic kidney disease: targeting prostaglandin E2 receptors," American Journal of Physiology Renal Physiology, vol. 307, no. 3, pp. F243- F250, 2014.
14. Z. Jia, Y. Sun, S. Liu, Y. Liu, and T. Yang, "COX-2 but not mPGES-1 contributes to renal PGE2 induction and diabetic proteinuria in mice with type-1 diabetes," PLoS ONE, vol. 9, no. 7, Article ID e93182, 2014.
15. H. Makino, I. Tanaka, M. Mukoyama et al., "Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1- selective antagonist," Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1757-1765, 2002.
16. M. D. Breyer and R.M. Breyer, "G protein-coupled prostanoid receptors and the kidney," Annual Review of Physiology, vol. 63, pp. 579-605, 2001.
17. Y. Yang,W. Ni,M. Cai,L. Tang, and W. Wei, "The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats," Journal of Receptors and Signal Transduction Research, vol. 34, no. 6, pp. 445-455, 2014.
18. R. Mohamed, C. Jayakumar, and G. Ramesh, "Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6," Laboratory Investigation, vol. 93, no. 8, pp. 933-945, 2013.
19. N. Nakagawa, K.-I. Yuhki, J.-I. Kawabe et al., "The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice," Kidney International, vol. 82, no. 2, pp. 158-171, 2012.
20. Y. Zhang, Y. Guan, A. Schneider, S. Brandon, R. M. Breyer, and M. D. Breyer, "Characterization of murine vasopressor and vasodepressor prostaglandin E2 receptors," Hypertension, vol. 35, no. 5, pp. 1129-1134, 2000.
21. M. D. Breyer and R. M. Breyer, "Prostaglandin receptors: their role in regulating renal function," Current Opinion in Nephrology and Hypertension, vol. 9, no. 1, pp. 23-29, 2000.
22. M. D. Breyer and R. M. Breyer, "Prostaglandin E receptors and the kidney," American Journal of Physiology. Renal Physiology, vol. 279, no. 1, pp. F12-F23, 2000.
23. A. G. Paul, B. Chandran, and N. Sharma-Walia, "Cyclooxygenase- 2-prostaglandin e2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies," Translational Research, vol. 162, no. 2, pp. 77-92, 2013.
24. A. Rios, H. vargas-Robles, A. M. G'amez-M'endez, and B. Escalante, "Cyclooxygenase-2 and kidney failure," Prostaglandins & Other Lipid Mediators, vol. 98, no. 3-4, pp. 86-90, 2012.
25. J. Hern'andez, H. Astudillo, and B. Escalante, "Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure," The American Journal of Physiology-Renal Physiology, vol. 282, no. 4, pp. F592-F598, 2002.
26. X. Liang, L. Wu, Q. Wang et al., "Function of COX-2 and prostaglandins in neurological disease," Journal of Molecular Neuroscience, vol. 33, no. 1, pp. 94-99, 2007.
27. L. R. Lopez, K. E. Guyer, I. G. Torre, K. R. Pitts, E. Matsuura, and P. R. Ames, "Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease," World Journal of Diabetes, vol. 5, no. 2, pp. 115-127, 2014.
28. P. Guillem-Llobat, M. Dovizio, S. Alberti, A. Bruno, and P. Patrignani, "Platelets, cyclooxygenases, and colon cancer," Seminars in Oncology, vol. 41, no. 3, pp. 385-396, 2014.
29. M. G. Perrone, A. Scilimati, L. Simone, and P. vitale, "Selective COX-1 inhibition: a therapeutic target to be reconsidered," Current Medicinal Chemistry, vol. 17, no. 32, pp. 3769-3805, 2010.
30. J. L. Wallace, "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?" Physiological Reviews, vol. 88, no. 4, pp. 1547-1565, 2008.
31. J. Schnermann and J. P. Briggs, "Tubular control of renin synthesis and secretion," Pflugers Archiv: European Journal of Physiology, vol. 465, no. 1, pp. 39-51, 2013.
32. R. C. Harris, M.-Z. Zhang, and H.-F. Cheng, "Cyclooxygenase- 2 and the renal renin-angiotensin system," Acta Physiologica Scandinavica, vol. 181, no. 4, pp. 543-547, 2004.
33. K. N.M. Khan, A. Burke, K. M. Stanfield, R. K. Harris, and D. A. Baron, "Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy," Renal Failure, vol. 23, no. 3-4, pp. 321-330, 2001.
34. R. C. Harris and M.-Z. Zhang, "Cyclooxygenase metabolites in the kidney," Comprehensive Physiology, vol. 1, no. 4, pp. 1729-1758, 2011.
35. H. Liu,W. Ye, G. Guan, Z. Dong, Z. Jia, and T. Yang, "Developmental regulation of calcineurin isoforms in the rodent kidney: association with COX-2," The American Journal of Physiology- Renal Physiology, vol. 293, no. 6, pp. F1898-F1904, 2007.
36. T. Yang, Y. G. Huang, W. Ye, P. Hansen, J. B. Schnermann, and J. P. Briggs, "Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice," American Journal of Physiology-Renal Physiology, vol. 288, no. 6, pp. F1125-F1132, 2005.
37. S. Agrawal, A. J. Guess, M. A. Chanley, and W. E. Smoyer, "Albumin-induced podocyte injury and protection are associated with regulation of COX-2," Kidney International, vol. 86, no. 6, pp. 1150-1160, 2014.
38. P. V. Ranganathan, C. Jayakumar, R. Mohamed, Z. Dong, and G. Ramesh, "Netrin-1 regulates the inflammatory response of neutrophils and macrophages, and suppresses ischemic acute kidney injury by inhibiting COX-2-mediated PGE2 production," Kidney International, vol. 83, no. 6, pp. 1087-1098, 2013.
39. Z. Jia, A. Zhang, H. Zhang, Z. Dong, and T. Yang, "Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion," Circulation Research, vol. 99, no. 11, pp. 1243-1251, 2006.
40. S. Soodvilai, Z. Jia, and T. Yang, "Hydrogen peroxide stimulates chloride secretion in primary inner medullary collecting duct cells via mPGES-1-derived PGE2," American Journal of Physiology-Renal Physiology, vol. 293, no. 5, pp. F1571-F1576, 2007.
41. C. S. Facemire, R. Griffiths, L. P. Audoly, B. H. Koller, and T.M. Coffman, "The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background," Hypertension, vol. 55, no. 2, pp. 531-538, 2010.
42. A. Schneider, Y. Zhang, M. Zhang et al., "Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney," Kidney International, vol. 65, no. 4, pp. 1205-1213, 2004.
43. T. Yang, "Microsomal prostaglandin e synthase-1 and blood pressure regulation," Kidney International, vol. 72, no. 3, pp. 274-278, 2007.
44. G. Yang, L. Chen, Y. Zhang et al., "Expression of mouse membrane-associated prostaglandin E2 synthase-2 (mPGES- 2) along the urogenital tract," Biochimica et Biophysica Acta- Molecular and Cell Biology of Lipids, vol. 1761, no. 12, pp. 1459-1468, 2006.
45. A. K. Lovgren, M. Kovarova, and B. H. Koller, "cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis," Molecular and Cellular Biology, vol. 27, no. 12, pp. 4416-4430, 2007.
46. Y. Nakatani, Y. Hokonohara, S. Kakuta, K. Sudo, Y. Iwakura, and I. Kudo, "Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal," Biochemical and Biophysical Research Communications, vol. 362, no. 2, pp. 387-392, 2007.
47. Y. Sun, Z. Jia, G. Yang et al., "mPGES-2 deletion remarkably enhances liver injury in streptozotocin-treated mice via induction of GLUT2," Journal of Hepatology, vol. 61, no. 6, pp. 1328-1336, 2014.
48. A. H. Moore, J. A. Olschowka, and M. K. O'Banion, "Intraparenchymal administration of interleukin-1β induces cyclooxygenase-2-mediated expression of membrane- and cytosolic-associated prostaglandin E synthases in mouse brain," Journal of Neuroimmunology, vol. 148, no. 1-2, pp. 32-40, 2004.
49. T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo, "Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis," The Journal of Biological Chemistry, vol. 275, no. 42, pp. 32775-32782, 2000.
50. M. Murakami, K. Nakashima, D. Kamei et al., "Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2," The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37937-37947, 2003.
51. Z. Jia, H. Wang, and T. Yang, "Mice lacking mPGES-1 are resistant to lithium-induced polyuria," The American Journal of Physiology-Renal Physiology, vol. 297, no. 6, pp. F1689-F1696, 2009.
52. S. Soodvilai, Z. Jia, M.-H. Wang, Z. Dong, and T. Yang, "mPGES-1 deletion impairs diuretic response to acute water loading,"TheAmerican Journal of Physiology-Renal Physiology, vol. 296, no. 5, pp. F1129-F1135, 2009.
53. Z. Jia, T. Aoyagi, D. E. Kohan, and T. Yang, "mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite," The American Journal of Physiology-Renal Physiology, vol. 299, no. 1, pp. F155-F166, 2010.
54. Z. Jia, T. Aoyagi, and T. Yang, "MPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP," Hypertension, vol. 55, no. 2, pp. 539-546, 2010.
55. Z. Jia, G. Liu, M. Downton, Z. Dong, A. Zhang, and T. Yang, "mPGES-1 deletion potentiates urine concentrating capability after water deprivation," American Journal of Physiology. Renal Physiology, vol. 302, no. 8, pp. F1005-F1012, 2012.
56. Z. Jia, X. Guo, H. Zhang, M.-H. Wang, Z. Dong, and T. Yang, "Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress," Hypertension, vol. 52, no. 5, pp. 952-959, 2008.
57. D.-J. Zhang, L.-H. Chen, Y.-H. Zhang et al., "Enhanced pressor response to acute Ang II infusion in mice lacking membraneassociated prostaglandin E2 synthase-1," Acta Pharmacologica Sinica, vol. 31, no. 10, pp. 1284-1292, 2010.
58. S. Parazzoli, J. S. Harmon, S. N. vallerie, T. Zhang, H. Zhou, and R. P. Robertson, "Cyclooxygenase-2, not microsomal prostaglandin E synthase-1, is the mechanism for interleukin- 1-β-induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets," The Journal of Biological Chemistry, vol. 287, no. 38, pp. 32246-32253, 2012.
59. Y. Sun, Z. Jia, G. Liu et al., "PPARγ agonist rosiglitazone suppresses renalmPGES-1/PGE2 pathway in db/db mice," PPAR Research, vol. 2013,Article ID 612971, 9 pages, 2013.
60. C. L. Pratt and C. R. Brown, "The role of eicosanoids in experimental Lyme arthritis," Frontiers in Cellular and Infection Microbiology, vol. 4, article 69, 2014.
61. T. Ganesh, "Prostanoid receptor EP2 as a therapeutic target," Journal of Medicinal Chemistry, vol. 57, no. 11, pp. 4454-4465, 2014.
62. T. Srivastava, U. S. Alon, P. A. Cudmore et al., "Cyclooxygenase- 2, prostaglandin E2, and prostanoid receptor EP2 in fluid flow shear stress-mediated injury in the solitary kidney," The American Journal of Physiology-Renal Physiology, vol. 307, no. 12, pp. F1323-F1333, 2014.
63. V. Konya, G. Marsche, R. Schuligoi, and A. Heinemann, "Etype prostanoid receptor 4 (EP4) in disease and therapy," Pharmacology &Therapeutics, vol. 138, no. 3, pp. 485-502, 2013.
64. J. W. Fisher and M. Hagiwara, "Effects of prostaglandins on erythropoiesis," Blood Cells, vol. 10, no. 2-3, pp. 241-260, 1984.
65. J. A. Ortega, P. P. Dukes, A. Ma, N. A. Shore, and M. H. Malekzadeh, "Aclinical trial of prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease. A preliminary report," Prostaglandins, Leukotrienes and Medicine, vol. 14, no. 3, pp. 411-416, 1984.
66. J. M. Arce, B. A. Naughton, G. A. Kolks, P. Liu, A. S. Gordon, and S. J. Piliero, "The effect of prostaglandins A2,E1,E2,15 methyl E2, 16, 16 dimethyl E2 and F2 alpha on erythropoiesis," Prostaglandins, vol. 21, no. 3, pp. 367-377, 1981.
67. J. W. Fisher, H. W. Radtke, W. Jubiz, P. K. Nelson, and A. Burdowski, "Prostaglandins activation of erythropoietin production and erythroid progenitor cells," Experimental Hematology, vol. 8, no. 8, pp. 65-89, 1980.
68. J. C. Pelayo and P. F. Shanley, "Glomerular and tubular adaptive responses to acute nephron loss in the rat. Effect of prostaglandin synthesis inhibition," The Journal of Clinical Investigation, vol. 85, no. 6, pp. 1761-1769, 1990.
69. P. L. Sanchez, L. M. Salgado, N. R. Ferreri, and B. Escalante, "Effect of cyclooxygenase-2 inhibition on renal function after renal ablation," Hypertension, vol. 34, no. 4, pp. 848-853, 1999.
70. O. Rådmark and B. Samuelsson, "Microsomal prostaglandin e synthase-1 and 5-lipoxygenase: potential drug targets in cancer," Journal of Internal Medicine, vol. 268, no. 1, pp. 5-14, 2010.
71. M. Nakanishi, V. Gokhale, E. J. Meuillet, and D.W. Rosenberg, "MPGES-1 as a target for cancer suppression. A comprehensive invited review 'Phospholipase A2 and lipid mediators'," Biochimie, vol. 92, no. 6, pp. 660-664, 2010.
72. H. Cheng, X. Fan, G. W. Moeckel, and R. C. Harris, "Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression," Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1240-1251, 2011.
73. H. Cheng, S. Wang, Y.-I. Jo et al., "Overexpression of cyclooxygenase-2 predisposes to podocyte injury," Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 551-559, 2007.
74. R. Mohamed, C. Jayakumar, P. V. Ranganathan, V. Ganapathy, and G. Ramesh, "Kidney proximal tubular epithelialspecific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice,"The American Journal of Pathology, vol. 181, no. 6, pp. 1991-2002, 2012.
75. R. Komers, J. Ždychov'a, M. Cahov'a, L. Kazdov'a, J. N. Lindsley, and S. Anderson, "Renal cyclooxygenase-2 in obese Zucker (fatty) rats," Kidney International, vol. 67, no. 6, pp. 2151-2158, 2005.
76. A. Dey, C. Maric,W. H. Kaesemeyer et al., "Rofecoxib decreases renal injury in obese Zucker rats," Clinical Science, vol. 107, no. 6, pp. 561-570, 2004.
77. J.-L. Wang, H.-F. Cheng, S. Shappell, and R. C. Harris, "A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats," Kidney International, vol. 57, no. 6, pp. 2334-2342, 2000.
78. P. Harding,W. F. Glass II, and S. D. Scherer, "COX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 68, no. 1, pp. 17-25, 2003.
79. D. Sankaran, N. Bankovic-Calic, M. R. Ogborn, G. Crow, and H. M. Aukema, "Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production inHan:SPRD-cy ratswith inherited kidney disease," American Journal of Physiology.Renal Physiology, vol. 293, no. 3, pp. F821-F830, 2007.
80. A. R. R. Goncälves, C. K. Fujihara, A. L. Mattar et al., "Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory," The American Journal of Physiology-Renal Physiology, vol. 286, no. 5, pp. F945-F954, 2004.
81. H. Cheng, X. Fan, Y. Guan, G. W. Moeckel, R. Zent, and R. C. Harris, "Distinct roles for basal and inducedCOX-2 in podocyte injury," Journal of the American Society of Nephrology, vol. 20, no. 9, pp. 1953-1962, 2009.
82. L. Feng, Y. Xia, G. E. Garcia, D. Hwang, and C. B. Wilson, "Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide," The Journal of Clinical Investigation, vol. 95, no. 4, pp. 1669-1675, 1995.
83. C. K. Fujihara, G. R. Antunes, A. L. Mattar et al., "Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney," Kidney International, vol. 64, no. 6, pp. 2172-2181, 2003.
84. A. Chronopoulos, M. H. Rosner, D. N. Cruz, and C. Ronco, "Acute kidney injury in elderly intensive care patients: a review," Intensive Care Medicine, vol. 36, no. 9, pp. 1454-1464, 2010.
85. A. Chronopoulos, M. H. Rosner, D. N. Cruz, and C. Ronco, "Acute kidney injury in the elderly: a review," Contributions to Nephrology, vol. 165, pp. 315-321, 2010.
86. S. G. Coca, "Acute kidney injury in elderly persons," American Journal of Kidney Diseases, vol. 56, no. 1, pp. 122-131, 2010.
87. A. Chronopoulos, D. N. Cruz, and C. Ronco, "Hospitalacquired acute kidney injury in the elderly," Nature Reviews Nephrology, vol. 6, no. 3, pp. 141-149, 2010.
88. R. Yilmaz and Y. Erdem, "Acute kidney injury in the elderly population," International Urology and Nephrology, vol. 42, no. 1, pp. 259-271, 2010.
89. K. W. Moon, J. Kim, J. H. Kim et al., "Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia," Rheumatology, vol. 50,no. 12,pp. 2278-2282, 2011.
90. G. L. Braden, M. H. O'Shea, J. G. Mulhern, and M. J. Germain, "Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors," Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1149-1153, 2004.
91. N. S. A. Patel, S. Cuzzocrea, M. Collino et al., "The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo," European Journal of Pharmacology, vol. 562, no. 1-2, pp. 148-154, 2007.
92. H. S. Hwang, K. J. Yang, K. C. Park et al., "Pretreatment with paricalcitol attenuates inflammation in ischemiareperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2," Nephrology Dialysis Transplantation, vol. 28, no. 5, pp. 1156-1166, 2013.
93. C. Q. Feitoza, N. O. S. Câmara, H. S. Pinheiro et al., "Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury," International Immunopharmacology, vol. 5, no. 1, pp. 79-84, 2005.